Segments - Anti-retroviral Drugs Market by Drugs Classes (Integrase Inhibitor, Protease Inhibitor, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside Reverse Transcriptase Inhibitors, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The Anti-retroviral Drugs Market was USD 32.49 Billion in 2022 and is likely to reach USD 58.24 Billion, expanding at CAGR of 6.7% during 2023 – 2031. The growth of the market is attributed to the rising burden of HIV, increasing investment in research and development and growing demand for of new and efficient drugs.
Antiretroviral drugs (ARV) are used to treat HIV. Approximately 37.9 million people worldwide are infected with HIV/AIDS. In 2018, an estimated 1.7 million people worldwide were infected with HIV. For unstable HIV strains, antiretroviral therapy can inhibit about 80% of HIV replication.
The report on the global Anti-retroviral Drugs Market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Anti-Retroviral drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Drugs Classes (Integrase Inhibitor, Protease Inhibitor, Multi-Class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
ViiV Healthcare, Merck & Co Inc., Gilead Sciences Inc., Bristol-Myers Squibb Company, and Boehringer Ingelheim International GmbH |
Based on drug classes, the market is segmented into integrase inhibitor, protease inhibitor, multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and others. The multi-class combination products segment is expected to represent a key market share during the forecast period owing to the rising number of multi-type combination products due to the increasing burden of HIV and the approval of new drugs.
According to the World Health Organization, about 770,000 people died of HIV in 2018. Many companies are focusing on development of innovative ARV therapy products to maintain competitive advantage and expand into new regional markets. Additionally, increasing funding for ARV drug development is expected to drive the growth of the market segment.
The nucleoside reverse transcriptase inhibitors segment and non-nucleoside reverse transcriptase inhibitors segment are anticipated to expand at a rapid pace during the forecast period. Some of the most widely used drugs in resource-limited areas use reverse transcriptase inhibitors due to the low genetic barriers. Moreover, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors are used to combat HIV and hepatitis infections through highly effective ARV therapy.
Integrase inhibitors, also known as integrase nuclear strand transfer inhibitors or INSTI, block the viral enzyme integrase, which is responsible for integrating viral DNA into the DNA of infected cells. Several integrase inhibitors are undergoing clinical trials. Raltegravir was the first drug approved by the FDA in October 2007. Raltegravir has two metal binding groups that compete with two Mg2+ ions for the substrate at the metal binding site of integrase. In early 2014, elvitegravir and dolutegravir were two other clinically approved integrase inhibitors.
Protease inhibitors block viral proteases, which are necessary for the formation of mature virus particles after budding from the host membrane. In particular, these drugs prevent the cleavage of gag and gag/pol precursor proteins. Viral particles produced in the presence of protease inhibitors are defective and in most cases are not infectious.
Some of the examples of HIV protease inhibitors are lopinavir, indinavir, nelfinavir, amprenavir and ritonavir. Darunavir and atazanavir are recommended as first-line treatments. Sensing inhibitors have similar effects by combining with glycosaminoglycans (GAGs), but the development of two experimental drugs in this category, Bevirimat and Vivecone, stopped in 2010. High resistance to certain protease inhibitors, second-generation drugs have been developed that can effectively combat other drug-resistant variants of HIV.
On the basis of regions, the anti-retroviral drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth is attributed to presence of market players, availability of healthcare infrastructure, rising awareness among citizens, and initiatives taken by the US government.
More than 56,000 new cases of HIV infection are found in the US each year, and about 20 out of every 100 infected people does not know that they are infected with the virus. The high coverage of ART and increasing attention to branded prescription drugs are expected to drive market growth in the region.
The global anti-retroviral drugs market has been segmented on the basis of
Key players competing in the anti-retroviral drugs market include ViiV Healthcare, Merck & Co Inc., Gilead Sciences Inc., Bristol-Myers Squibb Company, and Boehringer Ingelheim International GmbH.
Major players are involved in the development of new ARV drugs, especially drugs for the treatment of HIV. For instance, Gilead Sciences' Phase II clinical trial product GS-9131 is being developed for the treatment of HIV with reverse nucleosides.